Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2101
mi
from 91732
Gainesville, FL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Sarkis Clinical Trials
2101
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2318
mi
from 91732
South Miami, FL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Miami Research
2318
mi
from 91732
South Miami, FL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1717
mi
from 91732
Libertyville, IL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Capstone Clinical Research
1717
mi
from 91732
Libertyville, IL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1336
mi
from 91732
Overland Park, KA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Psychiatric Associates
1336
mi
from 91732
Overland Park, KA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1882
mi
from 91732
Lexington, KY
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
University Kentucky Psychiatry
1882
mi
from 91732
Lexington, KY
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2578
mi
from 91732
Boston, MA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1964
mi
from 91732
Rochester Hills, MI
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Rochester Center for Behavioral Medicine
1964
mi
from 91732
Rochester Hills, MI
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1831
mi
from 91732
Troy, MI
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Behavioral Medicine Center
1831
mi
from 91732
Troy, MI
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1558
mi
from 91732
St. Charles, MO
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
St Charles Psychiatric Associates
1558
mi
from 91732
St. Charles, MO
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
213
mi
from 91732
Las Vegas, NV
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Center for Psychiatry and Behavioral Medicine, Inc.
213
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2445
mi
from 91732
Mount Kisco, NY
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Bioscience Research, Llc
2445
mi
from 91732
Mount Kisco, NY
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2203
mi
from 91732
Durham, NC
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Duke University
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2218
mi
from 91732
Raleigh, NC
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Richard H. Weisler, MD, PA
2218
mi
from 91732
Raleigh, NC
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2363
mi
from 91732
Media, PA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Sequoia Behavioral Healthcare
2363
mi
from 91732
Media, PA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1212
mi
from 91732
Austin, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
FutureResearch Trials
1212
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1223
mi
from 91732
Dallas, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
FutureResearch Trials Dallas, LP
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
1349
mi
from 91732
Houston, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Bayou City Research, Ltd.
1349
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
2262
mi
from 91732
Herndon, VA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
NeuroScience, Inc. (NSI)
2262
mi
from 91732
Herndon, VA
Click here to add this to my saved trials
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Status: Enrolling
Updated:  5/5/2014
2320
mi
from 91732
Miami, FL
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Status: Enrolling
Updated: 5/5/2014
Ryder Trauma Center
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
25
mi
from 91732
Los Angeles, CA
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
UCLA Semel Institute
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
2244
mi
from 91732
Rochester, NY
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
Univ of Rochester Medical Center
2244
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
2375
mi
from 91732
Philadelphia, PA
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
UPENN Map Center for Mental Health Policy and Services Research
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Effect of Music Therapy on Cognitive Recovery
I. The Effect of Music Therapy on Cognitive Recovery From Pediatric Epilepsy Surgery
Status: Enrolling
Updated:  5/13/2014
1213
mi
from 91732
Austin, TX
Effect of Music Therapy on Cognitive Recovery
I. The Effect of Music Therapy on Cognitive Recovery From Pediatric Epilepsy Surgery
Status: Enrolling
Updated: 5/13/2014
Dell Children's Medical Center of Central Texas
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
103
mi
from 91732
San Diego, CA
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
University of California at San Diego
103
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
2301
mi
from 91732
Baltimore, MD
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
University of Maryland Medical Center, Shock Trauma Center
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
2121
mi
from 91732
Pittsburgh, PA
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
UPMC Presbyterian Hospital
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
2268
mi
from 91732
Richmond, VA
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
VCU Medical Center
2268
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
20
mi
from 91732
Los Angeles, CA
Cedars-Sinai Heart Institute
20
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Status: Enrolling
Updated:  5/27/2014
2439
mi
from 91732
Bronx, NY
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Status: Enrolling
Updated: 5/27/2014
Montefiore Medical Center, Albert Einstein College of Medicine
2439
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
17
mi
from 91732
Lakewood, CA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Center For United Research, Inc.
17
mi
from 91732
Lakewood, CA
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
347
mi
from 91732
Walnut creek, CA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Diablo Clinical Research Inc
347
mi
from 91732
Walnut creek, CA
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
2479
mi
from 91732
Milford, CT
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Clinical Research Consulting, LLC
2479
mi
from 91732
Milford, CT
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
2304
mi
from 91732
West Palm Beach, FL
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Metabolic Research Institute, Inc.
2304
mi
from 91732
West Palm Beach, FL
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
2588
mi
from 91732
New Bedford, MA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Novex Clinical Research, LLC
2588
mi
from 91732
New Bedford, MA
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
2190
mi
from 91732
Mt. Pleasant, SC
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Coastal Carolina Research Center
2190
mi
from 91732
Mt. Pleasant, SC
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
1226
mi
from 91732
Dallas, TX
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
North Texas Endocrine Center
1226
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
1223
mi
from 91732
Dallas, TX
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
KRK Research
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
1350
mi
from 91732
Houston, TX
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Houston Foot and Ankle Care
1350
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
565
mi
from 91732
Salt Lake City, UT
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Wasatch Clinical Research
565
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
951
mi
from 91732
Renton, WA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Rainier Clinical Research Center Inc.
951
mi
from 91732
Renton, WA
Click here to add this to my saved trials
Theta-burst Transcranial Magnetic Stimulation
Theta-burst Transcranial Magnetic Stimulation for the Treatment of Childhood Dystonia and Spasticity
Status: Enrolling
Updated:  5/28/2014
328
mi
from 91732
Stanford, CA
Theta-burst Transcranial Magnetic Stimulation
Theta-burst Transcranial Magnetic Stimulation for the Treatment of Childhood Dystonia and Spasticity
Status: Enrolling
Updated: 5/28/2014
Stanford University School of Medicine
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Status: Enrolling
Updated:  5/29/2014
1569
mi
from 91732
St Louis, MO
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Status: Enrolling
Updated: 5/29/2014
St Louis Children's Hospital
1569
mi
from 91732
St Louis, MO
Click here to add this to my saved trials
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Status: Enrolling
Updated:  5/29/2014
943
mi
from 91732
Seattle, WA
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Status: Enrolling
Updated: 5/29/2014
UWashington
943
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Status: Enrolling
Updated:  5/30/2014
1952
mi
from 91732
Hilliard, OH
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Status: Enrolling
Updated: 5/30/2014
Nationwide Children's Hospital Hilliard Close to Home
1952
mi
from 91732
Hilliard, OH
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
427
mi
from 91732
Tucson, AZ
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Arizona Medical Center
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
328
mi
from 91732
Stanford, CA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Stanford Univ Med Ctr
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
2486
mi
from 91732
New Haven, CT
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Yale University School of Medicine
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
2127
mi
from 91732
Jacksonville, FL
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Florida - Jacksonville
2127
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
1730
mi
from 91732
Chicago, IL
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Northwestern Memorial Hospital
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
1813
mi
from 91732
Louisville, KY
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Louisville Hospital
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials